C2 Pharma Menu
  • Products
      • c2p_navi_products_APIsProducts Image
      • Products
      • APIs
      • R&D PIPELINE
  • Services
  • Company
      • c2pharma_navi_aboutCompany Image
      • Company
      • ABOUT US
      • NETWORK
      • CAREERS
  • News
  • Contact

Category: Press Release

C2 PHARMA Receives CEP approval for Oxybuprocaine Hydrochloride

Posted on 28. January 202528. January 2025 by admin_c2p
Posted in Press Release

C2 PHARMA Receives CEP Approval For Tropicamide

Posted on 30. July 202430. July 2024 by admin_c2p
Posted in Press Release

C2 PHARMA’s Upcoming Launch of Oxybuprocaine Hydrochloride

Posted on 6. March 20246. March 2024 by admin_c2p
Posted in Press Release

C2 PHARMA Receives DMF Approval in China for Pilocarpine Nitrate

Posted on 21. November 202322. November 2023 by admin_c2p
Posted in Press Release

C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPhI Barcelona

Posted on 17. October 202317. October 2023 by admin_c2p
Posted in Press Release

EDQM Grants C2 PHARMA CEP Approval for Commercial Sale of Cyclopentolate Hydrochloride

Posted on 27. June 202327. June 2023 by admin_c2p
Posted in Press Release

C2 PHARMA Receives Approval for Digoxin China DMF, Becoming China’s Only European Supplier of This API

Posted on 13. June 202327. June 2023 by admin_c2p
Posted in Press Release

C2 PHARMA Completes Multiple Local Regulatory Filings and Expands Portfolio

Posted on 9. November 202116. May 2023 by admin
Posted in Press Release

C2 PHARMA Completes Multiple Regulatory Filings, Expands Portfolio

Posted on 23. February 202116. May 2023 by admin
Posted in Press Release

C2 PHARMA Acquires Digoxin API Portfolio from Nobilus Ent

Posted on 20. March 201923. February 2021 by admin
Posted in Press Release

Validation

Posted on 4. October 20183. October 2022 by admin
Posted in Press Release

C2 PHARMA leads

Posted on 4. October 20183. October 2022 by admin
Posted in Press Release

Acquisition

Posted on 22. June 20181. October 2018 by admin

Willkommen zur deutschen Version von WordPress. Dies ist der erste Beitrag. Du kannst ihn bearbeiten oder löschen. Und dann starte mit dem Schreiben!

Posted in Press Release

Recent Posts

  • C2 PHARMA Receives CEP approval for Oxybuprocaine Hydrochloride
  • C2 PHARMA Marks 10th Year Anniversary Attendance at CPhI Milan with Expanded Ophthalmic API Portfolio
  • C2 PHARMA EXPANDS OPHTHALMIC API PORTFOLIO WITH NAPHAZOLINE HYDROCHLORIDE LAUNCH
  • C2 PHARMA Receives CEP Approval For Tropicamide
  • C2 PHARMA’s Upcoming Launch of Oxybuprocaine Hydrochloride

Archives

  • January 2025
  • September 2024
  • July 2024
  • March 2024
  • February 2024
  • November 2023
  • October 2023
  • July 2023
  • June 2023
  • March 2023
  • February 2023
  • November 2022
  • October 2022
  • August 2022
  • November 2021
  • April 2021
  • February 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • September 2019
  • July 2019
  • June 2019
  • March 2019
  • November 2018
  • October 2018
  • June 2018
  • October 2017
  • September 2017
  • September 2016
  • October 2015
  • September 2015
  • May 2015
  • March 2015
  • September 2014

Categories

  • General
  • Information Brief
  • podcast
  • Press Release
  • Video

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • APIs

    • Atropine Sulfate
    • Bimatoprost
    • Brimonidine Tartrate
    • Cyclopentolate Hydrochloride
    • Digoxin
    • Digoxin Micronized
    • Homatropine Hydrobromide
    • Homatropine Methylbromide
    • Latanoprost
    • Naphazoline Hydrochloride
    • Oxybuprocaine Hydrochloride
    • Pilocarpine Hydrochloride
    • Pilocarpine Nitrate
    • Tropicamide
  • R&D Pipeline
  • Services
  • About Us
  • Network
  • Careers
  • News
Irish Green Logo 2024
  • CONTACT

info@c2pharma.com
C2Pharma Logo
  • General Terms of Sales
  • Data Privacy